Compare CCB & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | AMLX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2018 | 2021 |
| Metric | CCB | AMLX |
|---|---|---|
| Price | $74.19 | $13.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $126.67 | $20.11 |
| AVG Volume (30 Days) | 133.3K | ★ 843.7K |
| Earning Date | 04-28-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 3.06 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $96.61 | N/A |
| Revenue Next Year | $22.66 | N/A |
| P/E Ratio | $24.43 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $70.72 | $3.11 |
| 52 Week High | $120.05 | $17.49 |
| Indicator | CCB | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 45.73 |
| Support Level | $70.72 | $13.36 |
| Resistance Level | $118.72 | $15.37 |
| Average True Range (ATR) | 2.60 | 0.68 |
| MACD | 0.52 | -0.08 |
| Stochastic Oscillator | 5.08 | 22.82 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.